These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9794454)
21. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Gelling RW; Coy DH; Pederson RA; Wheeler MB; Hinke S; Kwan T; McIntosh CH Regul Pept; 1997 Apr; 69(3):151-4. PubMed ID: 9226399 [TBL] [Abstract][Full Text] [Related]
22. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. Gault VA; Parker JC; Harriott P; Flatt PR; O'Harte FP J Endocrinol; 2002 Nov; 175(2):525-33. PubMed ID: 12429050 [TBL] [Abstract][Full Text] [Related]
23. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321 [TBL] [Abstract][Full Text] [Related]
24. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Kerr BD; Flatt AJ; Flatt PR; Gault VA Biochem Biophys Res Commun; 2011 Jan; 404(3):870-6. PubMed ID: 21184739 [TBL] [Abstract][Full Text] [Related]
27. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Bhat VK; Kerr BD; Flatt PR; Gault VA Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155 [TBL] [Abstract][Full Text] [Related]
28. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Nakamura T; Tanimoto H; Mizuno Y; Tsubamoto Y; Noda H Diabetes Obes Metab; 2012 Jun; 14(6):511-7. PubMed ID: 22192426 [TBL] [Abstract][Full Text] [Related]
29. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors. Younan SM; Rashed LA Gen Physiol Biophys; 2007 Sep; 26(3):181-93. PubMed ID: 18063845 [TBL] [Abstract][Full Text] [Related]
35. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825 [TBL] [Abstract][Full Text] [Related]
36. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Gault VA; Flatt PR; Bailey CJ; Harriott P; Greer B; Mooney MH; O'harte FP Biochem J; 2002 Nov; 367(Pt 3):913-20. PubMed ID: 12150711 [TBL] [Abstract][Full Text] [Related]